GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CARsgen Therapeutics Holdings Ltd (HKSE:02171) » Definitions » EV-to-FCF

CARsgen Therapeutics Holdings (HKSE:02171) EV-to-FCF : -4.12 (As of Jun. 04, 2024)


View and export this data going back to 2021. Start your Free Trial

What is CARsgen Therapeutics Holdings EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, CARsgen Therapeutics Holdings's Enterprise Value is HK$2,090.81 Mil. CARsgen Therapeutics Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-508.04 Mil. Therefore, CARsgen Therapeutics Holdings's EV-to-FCF for today is -4.12.

The historical rank and industry rank for CARsgen Therapeutics Holdings's EV-to-FCF or its related term are showing as below:

HKSE:02171' s EV-to-FCF Range Over the Past 10 Years
Min: -8.71   Med: -1.32   Max: 2.08
Current: -4.27

During the past 5 years, the highest EV-to-FCF of CARsgen Therapeutics Holdings was 2.08. The lowest was -8.71. And the median was -1.32.

HKSE:02171's EV-to-FCF is ranked worse than
100% of 378 companies
in the Biotechnology industry
Industry Median: 8.345 vs HKSE:02171: -4.27

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-04), CARsgen Therapeutics Holdings's stock price is HK$6.59. CARsgen Therapeutics Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-1.465. Therefore, CARsgen Therapeutics Holdings's PE Ratio for today is At Loss.


CARsgen Therapeutics Holdings EV-to-FCF Historical Data

The historical data trend for CARsgen Therapeutics Holdings's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CARsgen Therapeutics Holdings EV-to-FCF Chart

CARsgen Therapeutics Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
- - -14.59 -7.08 -3.57

CARsgen Therapeutics Holdings Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only -14.59 - -7.08 - -3.57

Competitive Comparison of CARsgen Therapeutics Holdings's EV-to-FCF

For the Biotechnology subindustry, CARsgen Therapeutics Holdings's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CARsgen Therapeutics Holdings's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CARsgen Therapeutics Holdings's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where CARsgen Therapeutics Holdings's EV-to-FCF falls into.



CARsgen Therapeutics Holdings EV-to-FCF Calculation

CARsgen Therapeutics Holdings's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=2090.811/-508.042
=-4.12

CARsgen Therapeutics Holdings's current Enterprise Value is HK$2,090.81 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. CARsgen Therapeutics Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-508.04 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CARsgen Therapeutics Holdings  (HKSE:02171) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

CARsgen Therapeutics Holdings's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=6.59/-1.465
=At Loss

CARsgen Therapeutics Holdings's share price for today is HK$6.59.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. CARsgen Therapeutics Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-1.465.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


CARsgen Therapeutics Holdings EV-to-FCF Related Terms

Thank you for viewing the detailed overview of CARsgen Therapeutics Holdings's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


CARsgen Therapeutics Holdings (HKSE:02171) Business Description

Traded in Other Exchanges
Address
No. 388 Yindu Road, Building 12, CMC Preparation Center, Xuhui District, Shanghai, CHN
CARsgen Therapeutics Holdings Ltd is a global clinical-stage biopharmaceutical company discovering, researching and developing cell therapies in the People's Republic of China and the United States of America.
Executives
Guo Bingsen 2401 A concert party to an agreement to buy shares
Guo Huaqing 2101 Beneficial owner
Li Zonghai 2401 A concert party to an agreement to buy shares
Wang Huamao 2401 A concert party to an agreement to buy shares
Gic (ventures) Pte. Ltd. 2201 Interest of corporation controlled by you
Gic Private Limited 2201 Interest of corporation controlled by you
Gic Special Investments Private Limited 2102 Investment manager
Yang Zhi 2201 Interest of corporation controlled by you
Prowell Ventures Pte Ltd 2201 Interest of corporation controlled by you
Bvcf Realization Fund, L.p. 2201 Interest of corporation controlled by you
Bvcf Realization Fund Gp, Ltd. 2201 Interest of corporation controlled by you
Zhejiang Jolly Healthcare Investment Management Limited 2201 Interest of corporation controlled by you
Applied Biomaterial Ltd. 2201 Interest of corporation controlled by you
Zhejiang Jolly Pharmaceutical Co., Ltd. 2201 Interest of corporation controlled by you
Zhejiang Zuoli Innovation Medical Investment Management Co., Ltd. 2101 Beneficial owner

CARsgen Therapeutics Holdings (HKSE:02171) Headlines

No Headlines